Literature DB >> 1702332

Leukemia inhibitory factor/human interleukin for DA cells: a growth factor that stimulates the in vitro development of multipotential human hematopoietic progenitors.

C Verfaillie1, P McGlave.   

Abstract

We investigated the in vitro hematopoietic stimulatory activity of leukemia inhibitory factor/human interleukin for DA cells (LIF/HILDA) on bone marrow progenitor populations in 17 normal individuals. In serum-free cultures LIF/HILDA did not induce colony growth. In serum containing media, LIF/HILDA stimulated the growth of colony forming unit (CFU)-MIX and CFU-EO in a dose-dependent fashion and resulted in an increased CFU-MIX and burst forming unit-erythrocytes (BFU-E) colony size. Similar stimulatory effects were seen on a highly purified hematopoietic progenitor population obtained after immunomagnetic depletion of mature myeloid precursors and lymphoid cells. Addition of LIF/HILDA to cultures containing maximally stimulatory concentrations of recombinant human interleukin-3 (rhuIL3), rhuIL3 + rhuIL6, or rhu granulocyte-macrophage colony-stimulating factor (rhu GM-CSF) in serum containing media significantly increased the number of CFU-MIX and eosinophil colonies and increased size and cluster number of CFU-MIX and BFU-E. Depletion of accessory T lymphocytes or monocytes from bone marrow progenitors did not alter the response of hematopoietic precursors to LIF/HILDA. A similar increased colony growth was seen when LIF/HILDA was added to cultures of positively selected CD34/HLA-DR+ or CD34+/HLA-DR- bone marrow hematopoietic progenitor cells stimulated with maximally stimulatory concentrations of rhuIL3 + rhuIL6. LIF/HILDA is a novel cytokine capable of stimulating growth and proliferation of multi-lineage, erythroid, and eosinophil colonies in the presence of serum. LIF/HILDA exerts its activity by direct interaction with highly purified immature bone marrow progenitor cells, has an additive effect when used with other cytokines known to stimulate primitive hematopoietic precursors, and does not require accessory cells.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1702332

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  10 in total

1.  Replating of bioreactor expanded human bone marrow results in extended growth of primitive and mature cells.

Authors:  B O Palsson; D J Oh; M R Koller
Journal:  Cytotechnology       Date:  1995-01       Impact factor: 2.058

2.  Murine hematopoietic stem cells committed to macrophage/dendritic cell formation: stimulation by Flk2-ligand with enhancement by regulators using the gp130 receptor chain.

Authors:  D Metcalf
Journal:  Proc Natl Acad Sci U S A       Date:  1997-10-14       Impact factor: 11.205

3.  Interferon-alpha restores normal adhesion of chronic myelogenous leukemia hematopoietic progenitors to bone marrow stroma by correcting impaired beta 1 integrin receptor function.

Authors:  R Bhatia; E A Wayner; P B McGlave; C M Verfaillie
Journal:  J Clin Invest       Date:  1994-07       Impact factor: 14.808

4.  Treatment of marrow stroma with interferon-alpha restores normal beta 1 integrin-dependent adhesion of chronic myelogenous leukemia hematopoietic progenitors. Role of MIP-1 alpha.

Authors:  R Bhatia; P B McGlave; C M Verfaillie
Journal:  J Clin Invest       Date:  1995-08       Impact factor: 14.808

5.  Leukemia inhibitory factor is expressed in cartilage and synovium and can contribute to the pathogenesis of arthritis.

Authors:  M Lotz; T Moats; P M Villiger
Journal:  J Clin Invest       Date:  1992-09       Impact factor: 14.808

6.  Leukemia inhibitory factor secretion is a predictor and indicator of early progenitor status in adult bone marrow stromal cells.

Authors:  Mandolin J Whitney; Andy Lee; Joni Ylostalo; Suzanne Zeitouni; Alan Tucker; Carl A Gregory
Journal:  Tissue Eng Part A       Date:  2009-01       Impact factor: 3.845

7.  Reconstitution of SCID mice with human lymphoid and myeloid cells after transplantation with human fetal bone marrow without the requirement for exogenous human cytokines.

Authors:  T R Kollmann; A Kim; X Zhuang; M Hachamovitch; H Goldstein
Journal:  Proc Natl Acad Sci U S A       Date:  1994-08-16       Impact factor: 11.205

8.  Human multipotent stromal cells from bone marrow and microRNA: regulation of differentiation and leukemia inhibitory factor expression.

Authors:  Adam Z Oskowitz; Jun Lu; Patrice Penfornis; Joni Ylostalo; Jane McBride; Erik K Flemington; Darwin J Prockop; Radhika Pochampally
Journal:  Proc Natl Acad Sci U S A       Date:  2008-11-14       Impact factor: 11.205

Review 9.  LIF-dependent signaling: new pieces in the Lego.

Authors:  Marie-Emmanuelle Mathieu; Claire Saucourt; Virginie Mournetas; Xavier Gauthereau; Nadine Thézé; Vincent Praloran; Pierre Thiébaud; Hélène Bœuf
Journal:  Stem Cell Rev Rep       Date:  2012-03       Impact factor: 5.739

10.  Macrophage inflammatory protein 1 alpha, interleukin 3 and diffusible marrow stromal factors maintain human hematopoietic stem cells for at least eight weeks in vitro.

Authors:  C M Verfaillie; P M Catanzarro; W N Li
Journal:  J Exp Med       Date:  1994-02-01       Impact factor: 14.307

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.